[go: up one dir, main page]

AR075229A1 - Derivados de dihidroquinolinona. - Google Patents

Derivados de dihidroquinolinona.

Info

Publication number
AR075229A1
AR075229A1 ARP100100292A ARP100100292A AR075229A1 AR 075229 A1 AR075229 A1 AR 075229A1 AR P100100292 A ARP100100292 A AR P100100292A AR P100100292 A ARP100100292 A AR P100100292A AR 075229 A1 AR075229 A1 AR 075229A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
alkyls
cycloalkyl
atom
Prior art date
Application number
ARP100100292A
Other languages
English (en)
Inventor
Toshio Nakamura
Seiji Masuda
Aya Fujino
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of AR075229A1 publication Critical patent/AR075229A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Agente profiláctico o terapéutico para demencia, enfermedad de Alzheimer, trastorno de hiperactividad y déficit de atencion, esquizofrenia, trastornos de alimentacion, obesidad, diabetes, hiperlipidemia, trastornos del sueno, narcolepsia, síndrome de apnea de sueno, trastorno del ritmo circadiano, depresion, rinitis alérgica u otras enfermedades, composicion farmacéutica y usos. Reivindicacion 1: Un derivado de dihidroquinolinona representado por la formula (1) o una sal aceptable para uso farmacéutico del mismo [en la que Q representa la siguiente formula (2) o (3), R1 representa un átomo de hidrogeno, un átomo de halogeno o alquilo C1-6, R2 representa un átomo de hidrogeno o alquilo C1-6, n representa 1 o 2, R3 y R4, que pueden ser iguales o diferentes, representan cada uno alquilo C1-6 o cicloalquilo C3-7, o R3 y R4 están enlazados entre sí con su átomo de nitrogeno adyacente para formar un artillo heterocíclico saturado de 3 a 7 miembros (en donde dicho anillo heterocíclico saturado puede estar sustituido con uno o dos alquilos C1-6), R5 representa alquilo C1-6 (en el que dicho alquilo C1-6 puede estar sustituido con uno o dos cicloalquilos C3-7) o cicloalquilo C3-7 (en el que dicho cicloalquilo C3-7 puede estar sustituido con uno o dos alquilos C1-6), y P representa arilo, heteroarilo o heterociclilo {en donde dicho arilo, heteroarilo o heterociclilo puede estar sustituido con los mismos o diferentes 1 a 3 s sustituyentes seleccionados de: un átomo de halogeno, alquilo C1-6 (en el que dicho alquilo C1-6 puede estar sustituido con 1 a 3 átomos de halogeno, hidroxis, alcoxis C1-6 o dialquilaminos C2-12), alcoxi C1-6 (en donde dicho alcoxi C1-6 puede estar sustituido con 1 a 3 átomos de halogeno), amino, alquilamino C1-6, dialquilamino C2-12, alcanoilo C2-7, cicloalquilcarbonilo C4-8, ciano, alcoxicarbonilo C2-7, alquilaminocarbonilo C2-7, dialquilaminocarbonilo C3-13, carbonilo ligado a un anillo heterocíclico saturado monocíclico que contiene uno o más átomos de nitrogeno en el anillo y puede además contener un átomo de oxígeno o azufre, carbamoilo, heteroarilo, heterociclilo (en donde dicho heterociclilo puede estar sustituido con uno o dos alquilos C1-6), o heteroariloxi (en donde dicho heteroariloxi puede estar sustituido con uno o dos alquilos C1-6)}].
ARP100100292A 2009-02-06 2010-02-03 Derivados de dihidroquinolinona. AR075229A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009025462 2009-02-06
JP2009146735 2009-06-19

Publications (1)

Publication Number Publication Date
AR075229A1 true AR075229A1 (es) 2011-03-16

Family

ID=42026194

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100292A AR075229A1 (es) 2009-02-06 2010-02-03 Derivados de dihidroquinolinona.

Country Status (16)

Country Link
US (1) US8609847B2 (es)
EP (1) EP2393802B1 (es)
JP (1) JP5678889B2 (es)
KR (1) KR20110113734A (es)
CN (1) CN102307867A (es)
AR (1) AR075229A1 (es)
AU (1) AU2010211583A1 (es)
BR (1) BRPI1007369A2 (es)
CA (1) CA2750714A1 (es)
IL (1) IL214293A0 (es)
MX (1) MX2011008336A (es)
RU (1) RU2011136821A (es)
SG (1) SG173555A1 (es)
TW (1) TW201039822A (es)
WO (1) WO2010090347A1 (es)
ZA (1) ZA201105014B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
JP6218366B2 (ja) * 2012-09-04 2017-10-25 大正製薬株式会社 Ｈ３受容体の放射性標識リガンド
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
IN2014MU00197A (es) * 2014-01-21 2015-08-28 Wanbury Ltd
US9145388B2 (en) 2014-02-19 2015-09-29 King Fahd University Of Petroleum And Minerals 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones
CN104130187B (zh) * 2014-05-27 2017-02-15 浙江工业大学 一种手性二氢喹啉酮类化合物的不对称合成方法
CA3031425A1 (en) * 2015-10-30 2017-05-04 Trillium Therapeutics Inc. Heterocycle derivatives and their use for the treatment of cns disorders
CN110156676B (zh) * 2019-06-26 2020-11-03 绍兴文理学院 一种3,4-二氢喹啉-2(1h)-酮类衍生物及其制备方法与应用
CN114702428B (zh) * 2019-12-09 2023-11-28 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
CN115784983B (zh) * 2022-12-05 2024-09-27 井冈山大学 6-胺烷氧基-3,4-二氢喹啉酮衍生物及制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
JPS62135423A (ja) 1985-12-09 1987-06-18 Otsuka Pharmaceut Co Ltd 低酸素症改善剤
KR940000785B1 (ko) 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
JPH0681727B2 (ja) 1986-04-02 1994-10-19 大塚製薬株式会社 血小板粘着抑制剤
DK167187A (da) 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
US20060167046A1 (en) * 2002-09-18 2006-07-27 Eli Lilly And Company Patent Division Histamine h3 receptor antagonists, preparation and therapeutic uses
RU2358969C2 (ru) * 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
EP1761496A2 (en) 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
SI1747210T1 (sl) 2004-05-07 2010-09-30 Warner Lambert Co ali monosubstituirani fenolin in tiofenolni derivati uporabni kot ligandi H
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
JP4660553B2 (ja) 2004-10-19 2011-03-30 エフ．ホフマン−ラ ロシュ アーゲー キノリン誘導体
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
JPWO2006059778A1 (ja) 2004-12-01 2008-06-05 萬有製薬株式会社 置換ピリドン誘導体
RU2007125648A (ru) 2004-12-07 2009-01-20 Глэксо Груп Лимитед (GB) Инденильные производные и их применение для лечения неврологических расстройств
JP2008534542A (ja) 2005-03-31 2008-08-28 ユセベ ファルマ ソシエテ アノニム オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用
EP1868991B1 (en) 2005-04-01 2014-07-30 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP2007001944A (ja) * 2005-06-24 2007-01-11 Sankyo Agro Kk ３，４−ジヒドロ−１，３’−ビキノリン−２−オン誘導体

Also Published As

Publication number Publication date
US8609847B2 (en) 2013-12-17
TW201039822A (en) 2010-11-16
IL214293A0 (en) 2011-09-27
JP5678889B2 (ja) 2015-03-04
JP2012517400A (ja) 2012-08-02
RU2011136821A (ru) 2013-03-20
ZA201105014B (en) 2012-09-26
EP2393802A1 (en) 2011-12-14
US20120022064A1 (en) 2012-01-26
BRPI1007369A2 (pt) 2018-06-12
WO2010090347A1 (en) 2010-08-12
EP2393802B1 (en) 2013-05-08
SG173555A1 (en) 2011-09-29
AU2010211583A1 (en) 2011-09-01
MX2011008336A (es) 2011-08-24
CN102307867A (zh) 2012-01-04
KR20110113734A (ko) 2011-10-18
CA2750714A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
AR075229A1 (es) Derivados de dihidroquinolinona.
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
AR070517A1 (es) Piperidinas inhibidoras de 11 beta-hidroxiesteroide deshidrogenasa 1
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
AR038762A1 (es) Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
AR038237A1 (es) Aza-arilpiperazinas
AR073348A1 (es) Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1
AR044795A1 (es) Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
PE20080344A1 (es) Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
NO20083369L (no) Anvendelse av substituert 2-imidazol av imidazolinderivater
AR069207A1 (es) Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
PE20090820A1 (es) Derivados de piperidina/piperazina
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
BRPI0709773B8 (pt) derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer
AR049696A1 (es) Derivados de indol
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
AR058010A1 (es) Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto
PE20080277A1 (es) Derivados de azaindol espirociclicos y sustituidos
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
MX2010005225A (es) Derivados de fenilpirazol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal